ArticleFrontiers in neurology2026
Assessment of muscle damage in patients with advanced Duchenne muscular dystrophy based on serum creatinine and the height-to-creatinine ratio.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duchenne muscular dystrophy (DMD) is a fatal, X-linked neuromuscular disorder. This study investigated the correlation between serum markers and muscle damage in advanced DMD, retrospectively identified biochemical markers that reflect muscle damage in patients with advanced DMD, and provided a clinical basis for muscle assessment in advanced DMD. Methods: We enrolled 70 male patients with DMD who were treated at the Affiliated Hospital of the Institute of Neurology, Anhui University of Chinese Medicine, between January 2018 and December 2025. They were divided into an advanced group (≥12 years) and a non-advanced group (<12 years) based on age. We compared differences in serum creatinine (Scr), height-to-creatinine ratio, and creatine kinase (CK) levels between the two groups and used Spearman's rank correlation analysis to assess the association between these indicators and muscle damage. Results: The levels of Scr and CK in the advanced group were lower than those in the non-advanced group, while the height-to-creatinine ratio was higher ( Conclusion: Scr reflects changes in total skeletal muscle mass in patients with advanced DMD. In conjunction with the height-to-creatinine ratio, these parameters provide an assessment indicator for skeletal muscle damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.